Ask AI
Back Back
NSCLC EGFR Inhibitor Management FAQs
Practical Frequently Asked Questions From Pharmacists on Managing Patients With EGFR-Targeted Therapy in NSCLC

Released: June 12, 2026

Nina DiPierro
Nina DiPierro, PharmD, BCOP
Alia 'Lia' Lynch
Alia 'Lia' Lynch, PharmD, BCOP
Activity Information

Activity

Progress
1
Course Completed
Continue
Key Takeaways
  • Treatment with immunotherapy followed by EGFR-targeted therapy increases the risk of serious toxicities such as pneumonitis or immune-mediated hepatitis.
  • Amivantamab plus lazertinib is effective in treatment-naive patients with uncommon/atypical EGFR mutations.
  • Prophylactic anticoagulation is now recommended for the initial 4 months of treatment with amivantamab plus lazertinib to reduce the risk of VTE.

Staying the Course With EGFR-Targeted Therapy in NSCLC
EGFR-mutated non-small-cell lung cancer (NSCLC) care has become more individualized as new targeted strategies, bispecific antibodies, antibody–drug conjugates (ADCs), and supportive care protocols enter practice. In this commentary excerpted from a live program, Nina DiPierro, PharmD, BCOP, and Alia "Lia" Lynch, PharmD, BCOP, emphasize that treatment selection is no longer a one-size-fits-all approach; it requires careful attention to biomarker results, mutation subtype, disease burden, patient comorbidities, adverse event (AE) risk, treatment logistics, reimbursement, and patient preferences.

This complexity defines an important contribution for pharmacists, who can help ensure that biomarker results are available before systemic therapy decisions are finalized, reinforce patient counseling, coordinate medical and pharmacy benefit workflows, monitor for toxicities, and support early intervention so patients can stay on therapy when clinically appropriate.

Frequently Asked Questions

Why is it important to wait for biomarker testing results before starting first-line systemic therapy in advanced NSCLC?

Nina DiPierro, PharmD, BCOP:
Biomarker results can fundamentally reshape the optimal first-line approach. EGFR-mutated tumors often have limited benefit from standard immune checkpoint inhibitor approaches, and sequencing immunotherapy before an EGFR tyrosine kinase inhibitor (TKI) can increase the risk of serious toxicities such as pneumonitis or immune-mediated hepatitis. If a patient is clinically stable, waiting for molecular results helps avoid starting treatment that may be less effective or difficult to sequence safely. If treatment truly cannot wait, I would favor a chemotherapy doublet while holding immunotherapy until actionable driver results are available.

How should tissue and liquid biopsy be used when evaluating a patient for EGFR-mutated NSCLC?

Nina DiPierro, PharmD, BCOP:
Tissue-based testing remains the standard approach and is often available from the diagnostic biopsy, but liquid biopsy can be useful because it is less invasive and may return results more quickly. The tradeoff is that liquid biopsy can produce false-negative results, especially when tumor DNA shedding is low or a patient is responding to therapy. In practice, many teams use tissue and liquid testing in tandem when rapid results are needed or tissue is limited. The key is to use a platform that is broad enough to detect clinically relevant alterations and to understand each assay's strengths, turnaround time, and limitations.

How do EGFR mutation subtypes influence treatment selection?

Nina DiPierro, PharmD, BCOP:
EGFR-mutated NSCLC encompasses multiple subtypes rather than a single disease entity. In other words, not all EGFR mutations are the same, so treatment selection depends on the subtype. The most common EGFR- sensitizing alterations include exon 19 deletions and exon 21 L858R, and these have the strongest data for established EGFR-targeted therapies. Uncommon mutations such as G719X, S768I, and L861Q require a more nuanced approach because the evidence base is smaller, although afatinib and osimertinib have shown activity and newer combinations are being studied. At the 2026 ASCO annual meeting, data presented for the global, phase I/Ib CHRYSALIS-2 cohort C trial evaluating first-line amivantamab plus lazertinib showed encouraging durability in treatment-naive patients with atypical EGFR mutations, excluding Ex20ins and comutations with cEGFR, who had previously untreated advanced NSCLC. At ASCO 2026, investigators reported that after a median follow-up of approximately 31 months, the median OS was 41.0 months (95% CI: 27.7-NE), with 55% of patients alive at 3 years and 46% at 4 years, and no new safety signals. These data further support development of amivantamab plus lazertinib as a first-line option for this molecular subgroup.

When might a combination approach be considered instead of osimertinib alone in the frontline setting for metastatic NSCLC with a common EGFR mutation?

Alia "Lia" Lynch, PharmD, BCOP:
Frontline treatment decisions now require a more individualized discussion than they did when osimertinib monotherapy was the dominant standard. Combination approaches such as osimertinib plus chemotherapy or amivantamab plus lazertinib have shown improved outcomes in pivotal studies, but they also increase toxicity risk and clinic time and require monitoring and access considerations. Patient factors such as central nervous system involvement, high-risk comutations, performance status, kidney function, goals of care, and willingness or ability to come to clinic can all shape the discussion. The choice should be individualized through shared decision-making rather than assuming a single frontline regimen is appropriate for every patient.

What should be built into the care plan when a patient starts amivantamab plus lazertinib?

Nina DiPierro, PharmD, BCOP:
Supportive care should start at treatment initiation, not after toxicity has already interfered with daily life. For dermatologic toxicity, the phase II COCOON trial approach includes early oral doxycycline or minocycline, scalp-directed topical clindamycin after the oral antibiotic period, chlorhexidine for nails, and regular skin moisturization. This enhanced strategy was shown to reduce grade 2 or higher dermatologic AEs with the use of amivantamab plus lazertinib. Patients also need clear counseling to report rash, nail changes, scalp symptoms, dyspnea, or other new symptoms early so the care team can intervene before toxicity leads to unnecessary treatment interruption.

How should venous thromboembolism risk be addressed with amivantamab plus lazertinib?

Nina DiPierro, PharmD, BCOP:
Because amivantamab plus lazertinib was associated with increased venous thromboembolism (VTE) risk in the phase III MARIPOSA trial, with many events occurring during the first 4 months, prophylactic anticoagulation is now recommended for the initial 4 months of treatment. Clinically, new dyspnea during early therapy should not be dismissed as routine. Patients should be evaluated promptly for VTE, including possible pulmonary embolism, and the care team should determine whether the anticoagulation plan is appropriate for the individual patient.

What practical difference does subcutaneous amivantamab make compared with IV amivantamab?

Nina DiPierro, PharmD, BCOP:
Subcutaneous (SC) amivantamab can reduce treatment burden by shortening administration time and lowering infusion-related reaction (IRR) rates while maintaining efficacy. In the phase III PALOMA-3 trial, SC amivantamab plus lazertinib was associated with an IRR rate of 13% vs 66% with IV amivantamab plus lazertinib, with similar objective response rates (30% vs 33%, respectively). This can make treatment more tolerable for patients and reduce clinic time, although counseling should still include potential toxicities, supportive care, and the patient's overall treatment goals.

How should pharmacists counsel patients about dermatologic and gastrointestinal AEs with EGFR-targeted therapy?

Nina DiPierro, PharmD, BCOP:
Patients should understand that rash, dry skin, paronychia, and diarrhea are common and manageable when recognized early. Acneiform rash often appears within the first 2 weeks and may involve the face, chest, back, or scalp. Management may include moisturizers, topical steroids, tetracycline-class antibiotics, and dose holds or reductions depending on severity. Paronychia often occurs later and can become painful quickly, so nail trimming, loose-fitting shoes, avoiding aggressive manicures or pedicures, and early topical interventions matter. Diarrhea is more common with oral EGFR TKIs and is usually managed with antidiarrheals and supportive care, with dose modification when needed.

Why is repeat biomarker testing important when EGFR-mutated NSCLC progresses on therapy?

Alia "Lia" Lynch, PharmD, BCOP:
Resistance remains a major challenge even when initial therapy works well. At progression, repeat testing can identify on-target resistance mechanisms such as EGFR C797S, off-target mechanisms such as MET amplification or BRAF fusions, or histologic transformation to small-cell lung cancer. These findings can shape subsequent treatment selection. For example, the phase III SACHI study highlighted the potential value of targeting EGFR-mutated, MET-amplified NSCLC with savolitinib plus osimertinib after failure on EGFR TKI therapy. Without repeat testing, healthcare professionals may miss opportunities to tailor therapy based on the biology driving resistance.

What are the key toxicities to keep in mind for datopotamab deruxtecan in previously treated EGFR-mutated NSCLC?

Alia "Lia" Lynch, PharmD, BCOP:
Datopotamab deruxtecan (Dato-DXd) is a TROP2-directed ADC, so its safety profile is distinct from those of EGFR TKIs and amivantamab-based therapy. In the pooled analysis of TROPION-Lung01/Lung05, notable toxicities with Dato-DXd included stomatitis/oral mucositis and ocular surface events. Practical counseling includes prophylactic steroid-containing mouthwash when available, good oral hygiene, cryotherapy during infusion, avoiding irritating foods, lubricating eye drops, avoiding contact lenses when appropriate, and a baseline plus annual eye evaluation. These toxicities are often low grade but can be uncomfortable or clinically meaningful, so early counseling and monitoring are important.

How can specialty pharmacy teams help patients stay on EGFR-targeted therapy?

Nina DiPierro, PharmD, BCOP:
Specialty pharmacy teams can mitigate access and adherence barriers by following prescriptions from authorization through dispensing, coordinating benefits verification and prior authorization, identifying copay or foundation support, and communicating consistently with clinic pharmacists and other healthcare professionals. Since patients may receive oral, IV, or SC therapies across different pharmacy and medical benefit structures, there may be a chance of fragmented counseling. Clear documentation that includes potential drug interactions and toxicity monitoring plans, as well as well-coordinated handoffs, helps prevent duplication in some areas and gaps in others. This support is especially important as EGFR-mutated NSCLC care becomes more complex across lines of therapy.

Your Thoughts
Which EGFR-targeted therapy management issue is most challenging in your practice? Answer the polling question and leave a comment to share how your team coordinates biomarker testing, toxicity prevention, access support, and patient counseling.

Visit the program page and download the slides from the presentation for additional details on EGFR-mutated NSCLC treatment selection and toxicity management.

Continue

Poll

1.

Which issue is most challenging in your practice when caring for patients receiving EGFR-targeted therapy for NSCLC?

Submit